| Filed On | Filing |
|---|---|
| 26 May 2026 |
8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule
On May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance ... |
| 23 Dec 2025 |
8-K/A: Other Events
The following unaudited pro forma condensed combined financial information presents the unaudited pro forma condensed combined balance sheet and unaudited pro forma condensed combined statement of operations based upon the combined histo... |
| 17 Oct 2025 |
8-K/A: Entry into a Material Definitive Agreement
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of October 8, 2025, is entered into by and between TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), and Vstock Transfer, LLC, a California limited l... |
| 08 Oct 2025 |
8-K/A: Entry into a Material Definitive Agreement
This INVESTMENT AGREEMENT (this “Agreement”) is dated as of October 8, 2025, by and among TRANSCODE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and DEFJ, LLC, a Delaware limited liability company (the “Investor”). |
| 14 Jun 2024 |
8-K/A: Submission of Matters to a Vote of Security Holders
The following proposals were submitted to the stockholders at the 2024 Annual Meeting: |
Loading...
